Trial Outcomes & Findings for Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy (NCT NCT04831736)
NCT ID: NCT04831736
Last Updated: 2023-05-16
Results Overview
BPI Pain Severity Subscale consists of 4 questions (asking to rate pain). Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.
COMPLETED
PHASE4
31 participants
24 Hours Post-Op (Day 2)
2023-05-16
Participant Flow
Participant milestones
| Measure |
Treatment
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Overall Study
STARTED
|
15
|
16
|
|
Overall Study
COMPLETED
|
15
|
15
|
|
Overall Study
NOT COMPLETED
|
0
|
1
|
Reasons for withdrawal
| Measure |
Treatment
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
0
|
1
|
Baseline Characteristics
Effect of Postoperative Single Dose of Ketamine on Pain After Mastectomy
Baseline characteristics by cohort
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
Total
n=30 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
48.9 years
n=99 Participants
|
46.5 years
n=107 Participants
|
47.3 years
n=206 Participants
|
|
Sex: Female, Male
Female
|
15 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
30 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
15 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
30 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
11 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
20 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
15 participants
n=99 Participants
|
15 participants
n=107 Participants
|
30 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 24 Hours Post-Op (Day 2)BPI Pain Severity Subscale consists of 4 questions (asking to rate pain). Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score
|
16.7 score on a scale
Standard Deviation 6.97
|
18.1 score on a scale
Standard Deviation 8.44
|
PRIMARY outcome
Timeframe: 48 Hours Post-Op (Day 3)BPI Pain Severity Subscale consists of 4 questions (asking to rate pain). Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score
|
16 score on a scale
Standard Deviation 5.32
|
15.7 score on a scale
Standard Deviation 9.36
|
SECONDARY outcome
Timeframe: Baseline (Day 0)BPI Pain Severity Subscale is a 4-item questionnaire asking participants to rate pain. Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score
|
3.5 score on a scale
Standard Deviation 6.45
|
2.2 score on a scale
Standard Deviation 5.37
|
SECONDARY outcome
Timeframe: Day 7 Post-Op (Day 8)BPI Pain Severity Subscale is a 4-item questionnaire asking participants to rate pain. Each question is answered on a scale 0 (no pain) to 10 (pain as bad as you can imagine). The total range of score is 0-40; the higher the score, the worse the pain.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Brief Pain Inventory-short Form (BPI) Pain Severity Subscale Score
|
11.5 score on a scale
Standard Deviation 6.17
|
15 score on a scale
Standard Deviation 8.68
|
SECONDARY outcome
Timeframe: Baseline (Day 0)BPI Pain Interference Subscale is a 7-item questionnaire asking participants to describe how pain has interfered during activities. Each question is answered on a scale 0 (does not interfere) to 10 (completely interferes). The total range of score is 0-70; the higher the score, the worse the interference.
Outcome measures
| Measure |
Treatment
n=4 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=3 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Brief Pain Inventory-short Form (BPI) Pain Interference Subscale Score
|
35 score on a scale
Standard Deviation 18.29
|
35 score on a scale
Standard Deviation 30.35
|
SECONDARY outcome
Timeframe: Day 1 Post-Op (Day 2)BPI Pain Interference Subscale is a 7-item questionnaire asking participants to describe how pain has interfered during activities. Each question is answered on a scale 0 (does not interfere) to 10 (completely interferes). The total range of score is 0-70; the higher the score, the worse the interference.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Brief Pain Inventory-short Form (BPI) Pain Interference Subscale Score
|
24.7 score on a scale
Standard Deviation 17.1
|
28.1 score on a scale
Standard Deviation 14.9
|
SECONDARY outcome
Timeframe: Day 2 Post-Op (Day 3)BPI Pain Interference Subscale is a 7-item questionnaire asking participants to describe how pain has interfered during activities. Each question is answered on a scale 0 (does not interfere) to 10 (completely interferes). The total range of score is 0-70; the higher the score, the worse the interference.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Brief Pain Inventory-short Form (BPI) Pain Interference Subscale Score
|
33.5 score on a scale
Standard Deviation 12.5
|
32.1 score on a scale
Standard Deviation 15.5
|
SECONDARY outcome
Timeframe: Day 7 Post-Op (Day 8)BPI Pain Interference Subscale is a 7-item questionnaire asking participants to describe how pain has interfered during activities. Each question is answered on a scale 0 (does not interfere) to 10 (completely interferes). The total range of score is 0-70; the higher the score, the worse the interference.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Brief Pain Inventory-short Form (BPI) Pain Interference Subscale Score
|
33.9 score on a scale
Standard Deviation 18.3
|
32.9 score on a scale
Standard Deviation 15.1
|
SECONDARY outcome
Timeframe: Day of Surgery (Day 1)Use and dosage will be assessed through medical records and subject reports.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Total Dosage of Opioid Use
|
6 oral morphine equivalent (mg)
Standard Deviation 7.06
|
5 oral morphine equivalent (mg)
Standard Deviation 6.61
|
SECONDARY outcome
Timeframe: Day 1 Post-Op (Day 2)Use and dosage will be assessed through medical records and subject reports.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Total Dosage of Opioid Use
|
21.5 oral morphine equivalent (mg)
Standard Deviation 17.9
|
37.2 oral morphine equivalent (mg)
Standard Deviation 61.4
|
SECONDARY outcome
Timeframe: Day 2 Post-Op (Day 3)Use and dosage will be assess through medical records and subject reports.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Total Dosage of Opioid Use
|
21.2 oral morphine equivalent (mg)
Standard Deviation 31.1
|
18.5 oral morphine equivalent (mg)
Standard Deviation 21.2
|
SECONDARY outcome
Timeframe: Day 7 Post-Op (Day 8)Use and dosage will be assess through medical records and subject reports.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Total Dosage of Opioid Use
|
0.833 oral morphine equivalent (mg)
Standard Deviation 2.25
|
7 oral morphine equivalent (mg)
Standard Deviation 2.25
|
SECONDARY outcome
Timeframe: Baseline (Day 0)The PROMIS Fatigue Short Form consists of 7 questions evaluating the frequency of fatigue. Each question is answered with a score from 1 (never) to 5 (always). The raw score is the sum of each item and ranges from 7-35. Raw scores are converted to T-scores ranging from 31 to 81.4, with a standard deviation of 10. Higher T-scores indicate higher frequency of fatigue.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue (Short Form 7b) Daily Score
|
46.7 T-score
Standard Deviation 12.5
|
44.5 T-score
Standard Deviation 9.51
|
SECONDARY outcome
Timeframe: Day 1 Post-Op (Day 2)The PROMIS Fatigue Short Form consists of 7 questions evaluating the frequency of fatigue. Each question is answered with a score from 1 (never) to 5 (always). The raw score is the sum of each item and ranges from 7-35. Raw scores are converted to T-scores ranging from 31 to 81.4, with a standard deviation of 10. Higher T-scores indicate higher frequency of fatigue.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue (Short Form 7b) Daily Score
|
52.3 T-score
Standard Deviation 13.1
|
53.6 T-score
Standard Deviation 10.5
|
SECONDARY outcome
Timeframe: Day 2 Post-Op (Day 3)The PROMIS Fatigue Short Form consists of 7 questions evaluating the frequency of fatigue. Each question is answered with a score from 1 (never) to 5 (always). The raw score is the sum of each item and ranges from 7-35. Raw scores are converted to T-scores ranging from 31 to 81.4, with a standard deviation of 10. Higher T-scores indicate higher frequency of fatigue.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue (Short Form 7b) Daily Score
|
56.6 T-score
Standard Deviation 7.07
|
54 T-score
Standard Deviation 7.71
|
SECONDARY outcome
Timeframe: Day 7 Post-Op (Day 8)The PROMIS Fatigue Short Form consists of 7 questions evaluating the frequency of fatigue. Each question is answered with a score from 1 (never) to 5 (always). The raw score is the sum of each item and ranges from 7-35. Raw scores are converted to T-scores ranging from 31 to 81.4, with a standard deviation of 10. Higher T-scores indicate higher frequency of fatigue.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue (Short Form 7b) Daily Score
|
49.1 T-score
Standard Deviation 10.6
|
50.4 T-score
Standard Deviation 10.8
|
SECONDARY outcome
Timeframe: Baseline (Day 0)The PROMIS Sleep Disturbance Short Form consists of 6 items assessing sleep disturbance. Each question is answered with a score of 1-5 (varies). The raw score is the sum of each item and ranges from 6-30. The raw score is converted to a T-score ranging from 31.7 to 76.1, with a standard deviation of 10. Higher T-scores indicate greater sleep disturbance.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (Short Form 6A) Score
|
53.6 T-score
Standard Deviation 5.39
|
49.2 T-score
Standard Deviation 10.1
|
SECONDARY outcome
Timeframe: Day 7 Post-Op (Day 8)The PROMIS Sleep Disturbance Short Form consists of 6 items assessing sleep disturbance. Each question is answered with a score of 1-5 (varies). The raw score is the sum of each item and ranges from 6-30. The raw score is converted to a T-score ranging from 31.7 to 76.1, with a standard deviation of 10. Higher T-scores indicate greater sleep disturbance.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (Short Form 6A) Score
|
51.7 T-score
Standard Deviation 9.19
|
50.7 T-score
Standard Deviation 9.2
|
SECONDARY outcome
Timeframe: Baseline (Day 0)GAD-2 consists of 2 items and measures how often one has been bothered by anxiety-related problems. Each is answered with a score of 0 (not at all) to 3 (nearly every day). The total range of score is 0-6; the higher the score, the more frequent one is bothered by anxiety.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Generalized Anxiety Disorder (GAD-2) Score
|
2.47 score on a scale
Standard Deviation 1.77
|
1.87 score on a scale
Standard Deviation 2.07
|
SECONDARY outcome
Timeframe: Day 7 Post-Op (Day 8)GAD-2 consists of 2 items and measures how often one has been bothered by anxiety-related problems. Each is answered with a score of 0 (not at all) to 3 (nearly every day). The total range of score is 0-6; the higher the score, the more frequent one is bothered by anxiety.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Generalized Anxiety Disorder (GAD-2) Score
|
2.13 score on a scale
Standard Deviation 1.73
|
1.13 score on a scale
Standard Deviation 1.51
|
SECONDARY outcome
Timeframe: Day 7 Post-Op (Day 8)If the patient reports pain in the area of the breast, armpit, side of the body, or arm on the side of operation, the patient will be asked to report level of pain (0 is no pain and 10 is the worst pain imaginable). For each location, the total score is 0-10; the higher the score, the worse the pain. The total score is the sum of responses from each location.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Breast Cancer Pain Questionnaire (BCPQ) - Pain Score
|
3.53 score on a scale
Standard Deviation 2.56
|
4.6 score on a scale
Standard Deviation 2.72
|
SECONDARY outcome
Timeframe: Day 2 Post-Op (Day 3)Part A of QoR-15 consists of 10 conditions. Based on how the patient has been feeling in the last 24 hours, they will respond to each condition using an 11-point Likert scale ranging from 0 to 10, where 0 is none of the time \[poor\] and 10 is all of the time \[excellent\]). The total range of score for Part A is 0-100; the higher the score, the better the participant has been feeling. Part B consists of 5 symptoms. The patient will indicate whether they have experienced each symptom over the last 24 hours using an 11-point Likert scale ranging from 10 to 0, where 10 is none of the time \[excellent\] and 0 is all of the time \[poor\]). The total range of score for Part B is 0-50; the higher the score, the better the participant has been feeling. The total score is the sum of of scores from Parts A and B. Total scores range from 0-150; the higher the score, the better the participant has been feeling.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Quality of Recovery (QoR-15) Survey Score
|
75.1 score on a scale
Standard Deviation 12
|
74.6 score on a scale
Standard Deviation 13.2
|
SECONDARY outcome
Timeframe: Day 7 Post-Op (Day 8)Part A of QoR-15 consists of 10 conditions. Based on how the patient has been feeling in the last 24 hours, they will respond to each condition using an 11-point Likert scale ranging from 0 to 10, where 0 is none of the time \[poor\] and 10 is all of the time \[excellent\]). The total range of score for Part A is 0-100; the higher the score, the better the participant has been feeling. Part B consists of 5 symptoms. The patient will indicate whether they have experienced each symptom over the last 24 hours using an 11-point Likert scale ranging from 10 to 0, where 10 is none of the time \[excellent\] and 0 is all of the time \[poor\]). The total range of score for Part B is 0-50; the higher the score, the better the participant has been feeling. The total score is the sum of of scores from Parts A and B. Scores range from 0-150; the higher the score, the better the participant has been feeling.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Quality of Recovery (QoR-15) Survey Score
|
81.6 score on a scale
Standard Deviation 18.4
|
80.4 score on a scale
Standard Deviation 11.5
|
SECONDARY outcome
Timeframe: Day of Surgery (Day 1)Side effects are calculated using a 7-item psycho-behavioral questionnaire. Participants indicate whether they have experienced any of the listed side effects of ketamine. The side effects listed on the questionnaire are not considered to be Adverse Events or Serious Adverse Events.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Number of Participants Who Experience Side Effects
|
7 Participants
|
7 Participants
|
SECONDARY outcome
Timeframe: Day 1 Post-Op (Day 2)Side effects are calculated using a 7-item psycho-behavioral questionnaire. Participants indicate whether they have experienced any of the listed side effects. The side effects listed on the questionnaire are not considered to be Adverse Events or Serious Adverse Events.
Outcome measures
| Measure |
Treatment
n=15 Participants
Ketamine: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
|
Control
n=15 Participants
Placebo: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
|
|---|---|---|
|
Number of Participants Who Experience Side Effects
|
8 Participants
|
5 Participants
|
Adverse Events
Treatment
Control
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place